Pharmacological Treatment Strategies for Acute Bipolar Depression / 신경정신의학
Journal of Korean Neuropsychiatric Association
;
: 287-300, 2018.
Artículo
en Coreano
| WPRIM
| ID: wpr-718313
ABSTRACT
Of the different phases of bipolar disorder, bipolar depression is more prevailing and is more difficult to treat. However, there is a deficit in systemic research on the pharmacological treatment of acute bipolar depression. Therefore, consensuses on the pharmacological treatment strategies of acute bipolar depression has yet to be made. Currently, there are only three drugs approved by the Food and Drug Administration for acute bipolar depression quetiapine, olanzapine-fluoxetine complex, and lurasidone. In clinical practice, other drugs such as mood stabilizers (lamotrigine, lithium, valproate) and/or the other atypical antipsychotics (aripiprazole, risperidone, ziprasidone) are frequently prescribed. There remains controversy on the use of antidepressants in bipolar depression. Here, we summarized the evidence of current pharmacological treatment options and reviewed treatment guidelines of acute bipolar depression from recently published studies.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Antipsicóticos
/
United States Food and Drug Administration
/
Trastorno Bipolar
/
Risperidona
/
Consenso
/
Clorhidrato de Lurasidona
/
Fumarato de Quetiapina
/
Litio
/
Antidepresivos
Tipo de estudio:
Guía de Práctica Clínica
Idioma:
Coreano
Revista:
Journal of Korean Neuropsychiatric Association
Año:
2018
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS